Current guidelines for the treatment of congestive heart failure

Drugs

Volumn 51, Issue 1, 1996, Pages 89-98

  Kleber, Franz X ^a   Wensel, Roland ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS;

EID: 0030047392     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651010-00007     Document Type: Review

References (70)

1. Yusuf S, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989; 13: 174-9
2. McFate-Smith W. Epidemiology of congestive heart failure. Am J Cardiol 1985; 55 Suppl. A: 3-8
3. The SOLVD Investigators. Efect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
5. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22 Suppl. A:6A-13A
6. Poole-Wilson PA, Buller NP. Causes of symptoms in chronic congestive heart failure and implications for treatment. Am J Cardiol 1988; 62 (2): 31A-34A
7. Drexler H, Riede U, Munzel T, et al. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85 (5): 1751-9
8. Uretsky BF, Jessup M, Konstam MA, et al. Multicenler trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990; 82: 774-80
9. Packer M, Carver JR, Rodeheffer Rj, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75
10. DiBianco R, Shabatai R, Kostik W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677-83
11. Ribner J, Plucinski D, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56: 896-904
12. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22
13. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Circ Res 1981; 49: 618-26
14. Hammermeister KE, DeRouen TA, Dogde HT. Variables predictive of survival in patients with coronary disease: selection univariate and multivariate analyses from the clinical electrocardiographic, arteriographic, and quantitative angiographic evaluations. Circulation 1979; 59: 421-30
15. Anversa P, Olivetti G, Capaso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991; 68 (14): 7D-16D
16. Stein B, Fuster V, Halperin JL, et al. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989; 80: 1501-13
17. Fuster V, Gersh BJ, Guliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-31
18. Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolizalion. Ann Intern Med 1986; 104: 689-98
19. Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983; 2: 403-10
20. Chakki CS, Gherghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109: 497-504
21. Olshausen KV, Stienen U, Schwarz MF, et al. Long-term prognostic significance of ventricular arrhythmias in idiopathic cardiomyopathy. Am J Cardiol 1988; 61: 146-51
22. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72: 681-5
23. Jäschke R, Oxmann AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 1990; 88: 279-86
24. Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13: 134-42
25. Uretzky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild and moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-62
26. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin for patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. New Engl J Med 1993; 329: 1-7
27. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63: 225-7
28. Cowley AJ, Rowley JM, Stainer KL, et al. Captopril therapy for heart failure. A placebo controlled study. Lancet 1982; 2: 730-2
29. Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 1986; 74: 1303-8
30. Majid PA, Sharma B, Taylor SH. Phentolamine for vasodilator treatment of severe heart failure. Lancet 1971; 2: 719
31. Cohn JN, Archibald DG, Ziesche S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT I). N Engl J Med 1986; 314: 1547-52
32. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFt II). N Engl J Med 1991; 325: 303-10
33. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316 (23): 1429-35
34. Kleber FX, Niemöller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure. Results of the Munich Mild Heart Failure Trial (MHFT). Br Heart J 1992; 67: 289-96
35. Kleber FX, Niemöller L, Fischer M, et al. Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition. Am J Cardiol 1991; 68 (14): 121D-6D
36. Packer M. PRAISE: safety and survival of heart failure treated with amlodipine. European Congress of Cardiology. 1995 Aug
37. Cohn JN. V-HeFT III: efficacy and outcome with felodipine in heart failure. European Congress of Cardiology. 1995 Aug
38. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade in dilated cardiomyopathy. Circulation 1989; 80: 551-63
39. Chadda K, Goldstein S, Byington R, et al. Effects of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-10
40. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6
41. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73
42. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol 1994; 74: 674-80
43. Kahn JK. Anticoagulant treatment for atrial fibrillation. Postgrad Med 1992; 92: 119-24, 129-30
44. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175-9
45. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84 (2): 527-39
46. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323 (22): 1505-11
47. Connoly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18 (2): 349-55
48. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation 1994; 89 (3): 1469-75
49. Singh SN, Ross D, Fletcher SG, et al. Results of the Congestive Heart Failure Survival Trial of antiarrhythmic therapy (Veterans Affairs Cooperative Study Program #320). Circulation 1994; 90 (4): 1-546
50. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med 1991; 324: 781-8
51. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8
52. Morganroth J, Lichstein E, Byington R. Beta-Blocker Heart Attack Trial: impact of propranolol therapy on ventricular arrhythmias. Prev Med 1985 May; 14 (3): 346-57
53. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19: 842-50
54. Collaborative Group on ACE-Inhibitor Trials. Overview of randomised trials of angiotensin converting enzyme inhibitor on mortality and morbidity in patients with heart failure. JAMA. In press
55. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77
56. The Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755-63
57. Packer M, Hung W, Yushak M, et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl Med 1986; 315: 847-53
58. Riegger AJG, Kahles H, Fersti PB, et al. Akute Effekte eines neuen oral wirksamen Atriopeptidaseinhibitors (UK-79300) bei Patienten mit chronisch kongestiver Herzinsuffizienz. Klin Wochenschr 1990; 68: 269
59. Seneviratne B, Moore GA, West PD. Effect of captopril on function mitral regurgitation in dilated heart failure: a randomized double blind placebo controlled trial. Br Heart J 1994; 72: 63-8
60. Kleber FX, Niemöller L. Long-term survival in the Munich Mild Heart Failure Trial (MHFT). Am J Cardiol 1993; 71: 1237-9
61. Kleber FX. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases. Am J Hypertens. In press
62. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-44
63. Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993: 87 Suppl. VI: 78-87
64. Kleber FX, Niemöller L, Doering W. Sozio-ökonomische Bedeutung der ACE-mmer-Therapie bei Frühformen der Herzinsuffzienz. Munch Med Wochenschr 1992; 134: 749-52
65. Sharpe N, Smith H, Murphy J, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9
66. Bonaduce D, Petretta M, Arrichiello P, et al. Effects of captopril treatment on left ventricular remodeling and function after anterior myocardial infarction: comparison with digitalis. J Am Coll Cardiol 1992; 19: 858-63
67. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
68. Carlsen J, for the TRACE investigators. The TRACE (Trandolapril Cardiac Evaluation) study. European Congress of Cardiology. 1994 Aug
69. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
70. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial function. Gruppo Italiano per lo Studio della Sopravvivenza nell' infarcto Miocardico. Lancet 1994; 343: 1115-22